Cantor Fitzgerald Reaffirms Overweight Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday,Benzinga reports. They presently have a $4.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Monday, September 23rd. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. HC Wainwright restated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday. Finally, StockNews.com assumed coverage on Marinus Pharmaceuticals in a research report on Sunday, November 10th. They issued a “hold” rating for the company. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Stock Performance

Marinus Pharmaceuticals stock opened at $0.30 on Thursday. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The firm’s fifty day moving average price is $1.22 and its 200-day moving average price is $1.31. The stock has a market cap of $16.66 million, a P/E ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. The firm had revenue of $8.54 million during the quarter, compared to analyst estimates of $8.95 million. On average, analysts predict that Marinus Pharmaceuticals will post -1.92 earnings per share for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Suvretta Capital Management LLC raised its holdings in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after buying an additional 990,607 shares during the period. Vanguard Group Inc. boosted its stake in shares of Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after buying an additional 132,689 shares during the last quarter. abrdn plc grew its holdings in shares of Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after acquiring an additional 1,578,329 shares during the period. Finally, GSA Capital Partners LLP increased its position in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 817,050 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.